» Articles » PMID: 20598893

Synthesis and Pharmacological Evaluation of Pyrazine N-acylhydrazone Derivatives Designed As Novel Analgesic and Anti-inflammatory Drug Candidates

Abstract

In this paper, we report the synthesis and pharmacological evaluation of pyrazine N-acylhydrazone (NAH) derivatives (2a-s) designed as novel analgesic and anti-inflammatory drug candidates. This series was planned by molecular simplification of prototype 1 (LASSBio-1018), previously described as a non-selective cyclooxygenase inhibitor. Derivatives 2a-s were evaluated in several animal models of pain and inflammation, standing-out compound 2o (2-N'-[(E)-(3,4,5-trimethoxyphenyl) methylidene]-2-pyrazinecarbohydrazide; LASSBio-1181), that was also active in a murine model of chronic inflammation (i.e., adjuvant-induced arthritis test in rats) and can be considered a new analgesic and anti-inflammatory lead for drug development.

Citing Articles

Pyrazine derivative synthesis in a continuous-flow system: a green synthesis of pyrazinamide from pyrazine esters and amines catalyzed by Lipozyme® TL IM from .

Zhang A, Huang Z, Du L, Lin H, Xie H, Yan B RSC Adv. 2024; 14(53):39560-39568.

PMID: 39687336 PMC: 11648184. DOI: 10.1039/d4ra06761d.


Advancements in Pyrazine Derivatives as Anticancer Agents: A Comprehensive Review (2010-2024).

Alshahrani M Anticancer Agents Med Chem. 2024; 25(3):151-163.

PMID: 39318219 DOI: 10.2174/0118715206333399240912071555.


-Acylhydrazone Pharmacophore's Analgesic and Anti-inflammatory Profile: Recent Advancements during the Past Ten Years.

Kassab A Curr Pharm Des. 2024; 30(5):333-351.

PMID: 38303528 DOI: 10.2174/0113816128282470240117072322.


Acylhydrazones and Their Biological Activity: A Review.

Socea L, Barbuceanu S, Pahontu E, Dumitru A, Nitulescu G, Sfetea R Molecules. 2022; 27(24).

PMID: 36557851 PMC: 9783609. DOI: 10.3390/molecules27248719.


Synthesis of some new acylhydrazone compounds containing the 1,2,4-triazole structure and their neuritogenic activities in Neuro-2a cells.

Jiang X, Tang G, Yang J, Ding J, Lin H, Xiang X RSC Adv. 2022; 10(32):18927-18935.

PMID: 35518339 PMC: 9053900. DOI: 10.1039/d0ra02880k.